SCHEMBL5380215

SCHEMBL5380215

Clc1ccc(-c2c(-c3ccccc3Cl)nn3c(-c4ccc(Cl)cc4)ccnc23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.62
NPSR1 Q6W5P4 1/20 0.62
MAPT P10636 6/20 0.49
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NTRK1 P04629 4/20 0.47
PIM1 P11309 4/20 0.47
ACVR1 Q04771 2/20 0.46
GAA P10253 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GLA P06280 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
THRB P10828 2/20 0.44
CDK2 P24941 3/20 0.43
CHEK1 O14757 1/20 0.43
CSNK2A1 P68400 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5380218 0.88 NPC1 (0.47) NPC1NPSR1MAPTRAB9ASMN1; SMN2
SCHEMBL5375812 0.86 NPC1 (0.45) NPC1NPSR1MAPTRAB9ANTRK1
SCHEMBL5384163 0.81 NPC1 (0.44) NPC1NPSR1MAPTRAB9AKDM4E
SCHEMBL4842601 0.81 SRC (0.41) NPC1NPSR1RAB9ASMN1; SMN2ACVR1
SCHEMBL5380347 0.79 MAPK14 (0.43) NPC1NPSR1MAPTRAB9ATHRB
SCHEMBL5617770 0.79 CNR1 (0.42) NPC1NPSR1MAPTSMN1; SMN2GAA
SCHEMBL5380008 0.79 NPC1 (0.39) NPC1NPSR1MAPTRAB9AALDH1A1
SCHEMBL4833400 0.79 SRC (0.39) NPC1NPSR1RAB9ASMN1; SMN2ACVR1
SCHEMBL4836399 0.78 CNR1 (0.38) NPC1NPSR1RAB9AKDM4ETP53
SCHEMBL5377986 0.78 KMT2A (0.48) NPC1NPSR1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US claimed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US claimed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 NPC1 650/4885NPSR1 10/4885MAPT 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.